407 related articles for article (PubMed ID: 28605109)
1. A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute mania.
Weiser M; Levi L; Levine SZ; Bialer M; Shekh-Ahmad T; Matei V; Tiugan A; Cirjaliu D; Sava C; Sinita E; Zamora D; Davis JM
Bipolar Disord; 2017 Jun; 19(4):285-294. PubMed ID: 28605109
[TBL] [Abstract][Full Text] [Related]
2. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.
Sachs GS; Grossman F; Ghaemi SN; Okamoto A; Bowden CL
Am J Psychiatry; 2002 Jul; 159(7):1146-54. PubMed ID: 12091192
[TBL] [Abstract][Full Text] [Related]
3. Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial.
Bersudsky Y; Applebaum J; Gaiduk Y; Sharony L; Mishory A; Podberezsky A; Agam G; Belmaker RH
Bipolar Disord; 2010 Jun; 12(4):376-82. PubMed ID: 20636634
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania.
Ouyang WC; Hsu MC; Yeh IN; Kuo CC
Int J Psychiatry Clin Pract; 2012 Sep; 16(3):178-88. PubMed ID: 22404731
[TBL] [Abstract][Full Text] [Related]
5. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial.
Hirschfeld RM; Keck PE; Kramer M; Karcher K; Canuso C; Eerdekens M; Grossman F
Am J Psychiatry; 2004 Jun; 161(6):1057-65. PubMed ID: 15169694
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.
Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
Bipolar Disord; 2015 Feb; 17(1):63-75. PubMed ID: 25056368
[TBL] [Abstract][Full Text] [Related]
7. Risperidone in the treatment of mixed state bipolar patients: results from a 24-week, multicenter, open-label study in Korea.
Woo YS; Bahk WM; Jon DI; Chung SK; Lee SY; Ahn YM; Pae CU; Cho HS; Kim JG; Hwang TY; Lee HS; Min KJ; Lee KU; Yoon BH
Psychiatry Clin Neurosci; 2010 Feb; 64(1):28-37. PubMed ID: 19895394
[TBL] [Abstract][Full Text] [Related]
8. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
[TBL] [Abstract][Full Text] [Related]
9. Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms.
McIntyre RS; Konarski JZ; Jones M; Paulsson B
J Affect Disord; 2007; 100 Suppl 1():S5-14. PubMed ID: 17391773
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder.
Vieta E; Montgomery S; Sulaiman AH; Cordoba R; Huberlant B; Martinez L; Schreiner A
Eur Neuropsychopharmacol; 2012 Nov; 22(11):825-35. PubMed ID: 22503488
[TBL] [Abstract][Full Text] [Related]
11. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study.
Houston JP; Tohen M; Degenhardt EK; Jamal HH; Liu LL; Ketter TA
J Clin Psychiatry; 2009 Nov; 70(11):1540-7. PubMed ID: 19778495
[TBL] [Abstract][Full Text] [Related]
12. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group.
Müller-Oerlinghausen B; Retzow A; Henn FA; Giedke H; Walden J
J Clin Psychopharmacol; 2000 Apr; 20(2):195-203. PubMed ID: 10770458
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms.
Macfadden W; Adler CM; Turkoz I; Haskins JT; Turner N; Alphs L
BMC Psychiatry; 2011 Oct; 11():171. PubMed ID: 22034906
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.
Sachs GS; Vanderburg DG; Karayal ON; Kolluri S; Bachinsky M; Cavus I
J Clin Psychiatry; 2012 Nov; 73(11):1412-9. PubMed ID: 23218157
[TBL] [Abstract][Full Text] [Related]
15. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial.
Yatham LN; Grossman F; Augustyns I; Vieta E; Ravindran A
Br J Psychiatry; 2003 Feb; 182():141-7. PubMed ID: 12562742
[TBL] [Abstract][Full Text] [Related]
16. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial.
Weisler RH; Keck PE; Swann AC; Cutler AJ; Ketter TA; Kalali AH;
J Clin Psychiatry; 2005 Mar; 66(3):323-30. PubMed ID: 15766298
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder.
Katagiri H; Takita Y; Tohen M; Higuchi T; Kanba S; Takahashi M
Curr Med Res Opin; 2012 May; 28(5):701-13. PubMed ID: 22356118
[TBL] [Abstract][Full Text] [Related]
18. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.
Keck PE; Versiani M; Potkin S; West SA; Giller E; Ice K;
Am J Psychiatry; 2003 Apr; 160(4):741-8. PubMed ID: 12668364
[TBL] [Abstract][Full Text] [Related]
19. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study.
Haas M; Delbello MP; Pandina G; Kushner S; Van Hove I; Augustyns I; Quiroz J; Kusumakar V
Bipolar Disord; 2009 Nov; 11(7):687-700. PubMed ID: 19839994
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD).
Vieta E; Herraiz M; Fernández A; Gastó C; Benabarre A; Colom F; Martínez-Arán A; Reinares M
J Clin Psychiatry; 2001 Aug; 62(8):623-30. PubMed ID: 11561935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
